Yu-Sun Chang,
Chair Professor, Graduate Institute of Biomedical Sciences, and Molecular Medicine Research Center,
Chang Gung University
Yu-Sun Chang is the Chair Professor of Graduate Institute of Biomedical Sciences, Chang Gung University. The major research interest of Chang’s lab has been focusing on the role of Epstein-Barr virus in nasopharyngeal carcinoma (NPC) and the identification of clinically relevant biomarkers for susceptibility, predicting recurrence and metastasis, and monitoring of NPC. She is the founding director of the Chang Gung Molecular Medicine Research Center, which focus on Cancer Biomarker-related research. More recently, the group joined the CPTAC (Clinical Proteomic Tumor Analysis Consortium) and Cancer Moonshot (International Cancer Proteogenome Consortium) initiated by the National Cancer Institute, USA to extend its international collaboration on the integration of proteome and genome for cancer precision medicine.
Clinical Cancer Research via Integration of Next Generation Sequencing and Proteomic Technologies in Taiwanese Oral Squamous Cell Carcinoma
Thursday, 30 November 2017 at 17:00
Add to Calendar ▼2017-11-30 17:00:002017-11-30 18:00:00Europe/LondonClinical Cancer Research via Integration of Next Generation Sequencing and Proteomic Technologies in Taiwanese Oral Squamous Cell CarcinomaNext Generation Sequencing in the Clinic Asia Summit 2017 in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com
Oral squamous cell carcinoma (OSCC) is a prominent cancer worldwide, particularly in Taiwan. By integrating omics analyses in 50 matched samples, we uncover in Taiwanese patients a predominant mutation signature associated with cytidine deaminase APOBEC, which correlates with the up-regulation of APOBEC3A expression in the APOBEC3 gene cluster at 22q13. APOBEC3A expression is significantly higher in tumors carrying APOBEC3B-deletion allele(s). High-level APOBEC3A expression is associated with better overall survival, especially among patients carrying APOBEC3B-deletion alleles, as examined in a second cohort (n=188; p=0.004). Interestingly, the high frequency (50%) of APOBEC3B-deletion alleles is detected in OSCC-Taiwan samples, but not in OSCC-TCGA samples (5.8%, n= 314). Through the integrated omics analyses, we thus identify a frequent APOBEC mutational profile, which relates to a APOBEC3B-deletion germline polymorphism in Taiwanese OSCC that impacts expression of APOBEC3A, and is shown to be of clinical prognostic relevance. Our study emphasizes the importance of integration of multiple omics data for cancer precision medicine research in the future.
Add to Calendar ▼2017-11-30 00:00:002017-11-30 00:00:00Europe/LondonNext Generation Sequencing in the Clinic Asia Summit 2017Next Generation Sequencing in the Clinic Asia Summit 2017 in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2017-11-30 17:00:002017-11-30 18:00:00Europe/LondonClinical Cancer Research via Integration of Next Generation Sequencing and Proteomic Technologies in Taiwanese Oral Squamous Cell CarcinomaNext Generation Sequencing in the Clinic Asia Summit 2017 in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com
